首页> 外文期刊>Canadian Urological Association Journal >Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort
【24h】

Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort

机译:腹腔镜治疗pT3肾肿块后的临床结局:大型,多机构队列

获取原文
           

摘要

Introduction: We described the clinical and oncological outcomes of patients treated by laparoscopic surgery for non-metastatic pT3 renal cell carcinoma (RCC). Methods: We queried a multi-institutional database for patients diagnosed with non-metastatic pathological T3 RCC from 13 Canadian centres treated laparoscopically (radical or partial nephrectomy) between 2008 and 2014. Clinical and pathological outcomes were evaluated. Progression was defined as the development of recurrence or metastatic disease. Log-rank testing and Kaplan-Meier statistical methods assessed for differences and estimated progression-free survival (PFS). Results: In total, 176 patients were identified with a median age of 64 years. The median tumour size was 7.0 cm. Pre-clinical stage was cT1 to cT4 in 39%, 28%, 30% and 3%, respectively. The median blood loss was 150 mL (range: 0–6000) and the median operative time was 124 minutes (range: 60–360). Most lesions were clear cell RCC (80%). After a median follow-up of 17.6 months (range: 0.2–75.0), disease progression occurred in 26% (46/176) of patients, consisting of local recurrence in 7% (3/46), and metastatic disease in 93% (43/46). The 3-year PFS was 67%, with a median PFS of 49 months. Of those who progressed, the median time to progression was 10.3 months. Conclusions: This study is the largest cohort of pT3 RCC patients treated laparoscopically in the literature and suggests that for properly selected patients, laparoscopic management of locally advanced renal masses yields acceptable short-term oncological outcomes.
机译:简介:我们描述了腹腔镜手术治疗非转移性pT3肾细胞癌(RCC)的患者的临床和肿瘤学结局。方法:我们从2008年至2014年间,从13个加拿大中心经腹腔镜(根治性或部分肾切除术)治疗的患者中,查询了一个多机构数据库,以诊断为非转移性病理T3 RCC。进展被定义为复发或转移性疾病的发展。对数秩检验和Kaplan-Meier统计方法评估了差异并估计了无进展生存期(PFS)。结果:总共鉴定出176名患者,中位年龄为64岁。中位肿瘤大小为7.0cm。临床前阶段分别是cT1至cT4的39%,28%,30%和3%。平均失血量为150 mL(范围:0–6000),平均手术时间为124分钟(范围:60–360)。多数病变为透明细胞RCC(80%)。在中位随访17.6个月(范围:0.2-75.0)后,有26%(46/176)的患者发生了疾病进展,其中局部复发为7%(3/46),转移性疾病为93% (43/46)。 3年PFS为67%,中位PFS为49个月。在那些进展的患者中,进展的中位时间为10.3个月。结论:这项研究是在文献腹腔镜治疗肿瘤pT3 RCC患者的最大的队列,并表明,对于正确选择的患者,局部晚期肾肿瘤的腹腔镜手术产生可接受的短期肿瘤学结果。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号